Effects of ghrelin treatment on exertional dyspnea in COPD: an exploratory analysis

Table 3 Changes in break-points during pulmonary rehabilitation with ghrelin or placebo

Data are presented as mean difference, i.e., ghrelin minus placebo (SD). Dyspnea, noradrenaline, and lactate break-points with ghrelin were determined for 9, 9, and 8 patients, respectively, and with placebo for 7, 7, and 6 patients, respectively
%, ratio of each oxygen uptake (\({\dot{V}}_{{\rm O}_{2}}\)) at the break-point to Δ\({\dot{V}}_{{\rm O}_{2}}\) (peak \({\dot{V}}_{{\rm O}_{2}}\)− resting \({\dot{V}}_{{\rm O}_{2}}\)). Treatment effect: mean difference from pre-treatment (ghrelin minus placebo)
^aBetween-group difference (treatment effect) by unpaired t-test

ISSN: 1880-6562